ライフサイエンスコーパス: subcutaneous injection

1 three doses 4 weeks apart), or placebo (all subcutaneous injection).

2 female animals (1000 U/kg EPO or CEPO; three subcutaneous injections).

3 y correlated with their concentrations after subcutaneous injection.

4 al level for prolonged period after a single subcutaneous injection.

5 -siRNA into mice through either tail vein or subcutaneous injection.

6 unotherapy via laser-generated micropores to subcutaneous injection.

7 drogel combination that lasted 4 weeks after subcutaneous injection.

8 the 2009 H1N1 influenza virus, compared with subcutaneous injection.

9 treatment option instead of a more expensive subcutaneous injection.

10 tal microneedles (MN) applied to skin or via subcutaneous injection.

11 in vivo sodium concentration detectors after subcutaneous injection.

12 cynomolgus monkeys and is bioavailable after subcutaneous injection.

13 d the spleen after either intraperitoneal or subcutaneous injection.

14 ab and placebo were administered by means of subcutaneous injection.

15 capture viral particles within minutes after subcutaneous injection.

16 ps or a replacement dose given once daily by subcutaneous injection.

17 ction techniques, as opposed to conventional subcutaneous injection.

18 nercept or placebo (vehicle) by twice-weekly subcutaneous injection.

19 intestinal lumen was absorbed, relative to a subcutaneous injection.

20 and properties was compared by 3T MRI after subcutaneous injection.

21 e by means of either aerosol inhalation or a subcutaneous injection.

22 most previous studies, cocaine was given via subcutaneous injections.

23 weight gain, hypoglycaemia, and the need for subcutaneous injections.

24 tment through both intravenous and non-local subcutaneous injections.

25 ks or 420 mg monthly) or matching placebo as subcutaneous injections.

26 g, n = 9) or placebo (n = 8), as six monthly subcutaneous injections.

27 significant difference (p>0.05) compared to subcutaneous injection (24+/-13min).

28 e glucocorticoid dexamethasone (10 mg/kg) by subcutaneous injection 30 minutes postinjury restores le

29 rats (n=18 male, n=18 female) received daily subcutaneous injections (40 microg/kg body weight) of BP

30 Chronic nicotine treatment (two daily subcutaneous injections administered approximately 12 h

31 In conclusion, fondaparinux subcutaneous injection afforded significant advantages i

32 AAA animals (N = 15) underwent daily saline subcutaneous injection after PPE exposure.

33 ndaparinux because it does not require daily subcutaneous injection and is cheaper.

34 e of trafficking to the tumor site following subcutaneous injection and modulates transcription of se

35 e limitations of current DHE formulations in subcutaneous injection and nasal spray such as pain, adv

36 With the convenience of a subcutaneous injection and no requirement for renal moni

37 Subcutaneous injections and the sublingual route have be

38 tion route with the high efficacy known from subcutaneous injections and therefore represents a promi

39 ortezomib (1.3 mg/m(2); intravenous bolus or subcutaneous injection) and dexamethasone (20 mg oral or

40 imposed on CKD (5000 U/kg EPO or CEPO; three subcutaneous injections) and ischemia-reperfusion-induce

41 ated with AMD3100 at a dose of 240 mug/kg by subcutaneous injection, and leukapheresis was then initi

42 acept, 2.2 mg/kg (maximum, 160 mg) by weekly subcutaneous injection, and two 3-month courses of place

43 Notably, intravenous and subcutaneous injections are the only routes of administr

44 t hardly penetrated into the lungs following subcutaneous injection, as opposed to pulmonary delivery

45 ated with rhEndostatin administered as a bid subcutaneous injection at a starting dose of 60 mg/m2/d.

46 The agonist was administered by subcutaneous injection at an initial dose of 0.05 mg per

47 gical tracer molecule) and delivered in five subcutaneous injections at 21-day intervals to 10 cervic

48 study patients were randomized to receive 6 subcutaneous injections at 4-week intervals of either 30

49 , 16 or 32 mg/kg) at 1 h post-occlusion, and subcutaneous injections at 6 h and then once every 24 h

50 or vehicle at 1 h post-occlusion followed by subcutaneous injections at 6, 24 and 48 h.

51 treatment with the 5-HT1A agonist 8-OH-DPAT (subcutaneous injections at a dose of 0.15 mg/kg) retarde

52 anti-TNF therapy were randomized to receive subcutaneous injections at weeks 0 and 2 with adalimumab

53 ,000 units) or a placebo was administered by subcutaneous injection before day 7 of long-term acute c

54 Voclosporin administration, by subcutaneous injection, began on day (d) 0 or d7 after i

55 erophore were both essentially avirulent via subcutaneous injection (bubonic plague model).

56 The amount of BA detected in muscle after subcutaneous injection correlated with the distance from

57 PR65 was administered by subcutaneous injection daily for 2 weeks to iron-deplete

58 ive alirocumab (150 mg) or placebo as a 1-ml subcutaneous injection every 2 weeks for 78 weeks.

59 TEV-48125 given by subcutaneous injection every 28 days seems to be tolerab

60 ts) PF03512676 adjuvant were administered by subcutaneous injection every 3 weeks for a total of 4 in

61 r 300 mg in METREO) with placebo, given as a subcutaneous injection every 4 weeks for 52 weeks in pat

62 Patients received a 40 mg adalimumab subcutaneous injection every other week for 6 months.

63 Study drugs were given as two subcutaneous injections every 4 weeks for the first thre

64 than intracerebroventricular administration; subcutaneous injections extended the median lifespan by

65 6h in chemical-induced diabetes mice, while subcutaneous injection failed to maintain blood glucose

66 75 mg/m2/d was administered once daily as a subcutaneous injection for 5 to 21 days in combination w

67 atio), with study drug administered by daily subcutaneous injection for 6 months.

68 (420 mg) (n = 484) or placebo (n = 484) via subcutaneous injection for 76 weeks, in addition to stat

69 Subjects received 100 mg anakinra by subcutaneous injection for 84 days, followed by a 180-da

70 tiramer acetate (20 mg), or placebo by daily subcutaneous injection for 9 months.

71 ated with etanercept (25 mg twice weekly, by subcutaneous injection) for 24 weeks.

72 Patients received T-1249 monotherapy by subcutaneous injection, for 14 days, at doses ranging fr

73 However, subcutaneous injection had only marginal effects on morp

74 mulated strong IFN-alpha responses following subcutaneous injection, had robust antiviral activity th

75 insulin inhalation is two times greater than subcutaneous injection; however, the insulin is present

76 To desensitize allergic individuals, subcutaneous injection immunotherapy or sublingual immun

77 Osmopump delivery but not subcutaneous injection improved hyperalgesia and restore

78 Following subcutaneous injection in a diabetic rat, the analog eff

79 -retinoids was achieved in Lrat(-/-) mice by subcutaneous injection in a microparticle/hydrogel drug-

80 ation of (99m)Tc-SPIONs in lymph nodes after subcutaneous injection in animals, verified by SPECT/MRI

81 gents reach therapeutic concentrations after subcutaneous injection in nonhuman primates.

82 g-dose trial of inclisiran administered as a subcutaneous injection in patients at high risk for card

83 by intra-oral injection was as effective as subcutaneous injection in promoting tooth extraction soc

84 C3H mice received subcutaneous injections in the flank of a cell suspensio

85 NO2-Tyr(166)-apoA-I, after subcutaneous injection into hLCAT(Tg/Tg), apoA-I(-/-) mi

86 m patient-derived xenografts was assessed by subcutaneous injection into nonobese diabeteic.Cg-Prkdc(

87 ho(-/-) mice at postnatal day 10 as a single subcutaneous injection mixed with a basement membrane ma

88 Noxious stimulation of the hind paw by subcutaneous injection of 0.5% formalin into the dorsum

89 A single subcutaneous injection of 10(5) PFU diminished the paras

90 After a single subcutaneous injection of 100 microg/kg, approximately 1

91 ntation in nude or syngeneic mice, following subcutaneous injection of 2 human and 2 murine tumors.

92 The first cohort received one subcutaneous injection of 2 mg/kg RG-101 or placebo; the

93 EIU was induced by a subcutaneous injection of 200 microg lipopolysaccharide

94 water, in response to hypovolemia induced by subcutaneous injection of 30% polyethylene glycol soluti

95 1 or placebo; the second cohort received one subcutaneous injection of 4 mg/kg or placebo.

96 Patients received 1 subcutaneous injection of 60 mg gevokizumab at baseline

97 enerated randomisation schedule to receive a subcutaneous injection of 7.5 mg, 22.5 mg, 75 mg, or 225

98 eceiving an anti-myostatin PINTA745 (n = 12; subcutaneous injection of 7.5 mg.kg(-1) PINTA745 immedia

99 In WT mice in vivo, subcutaneous injection of 8-OH-DPAT produced similar bip

100 puter-generated random sequence to receive a subcutaneous injection of 80 mg ixekizumab every 4 weeks

101 models: xenografts produced in F344 rats by subcutaneous injection of 9L tumor cells and transgenic

102 In the first arm of the study, subcutaneous injection of A6 (200 mg/kg per day) into th

103 dle cell/pleomorphic sarcomas after a single subcutaneous injection of adenovirus carrying Cre-recomb

104 Morphologically, subcutaneous injection of all PPCLs into mice yielded tu

105 ients, respectively, were treated with daily subcutaneous injection of AM0010.

106 assessed by comparison with intradermal and subcutaneous injection of antigen using a 27G needle and

107 Dermal fibrosis was induced by subcutaneous injection of bleomycin into the dorsal skin

108 opathy, NaV1.8 shRNA vector was delivered by subcutaneous injection of cationized gelatin/plasmid DNA

109 tulated in experimentally induced lesions by subcutaneous injection of CCL27 and TNF in unaffected Hn

110 Interestingly, tumors formed by subcutaneous injection of cells metastasize not only to

111 al growth factor (VEGF)-2 gene transfer plus subcutaneous injection of CKs; VEGF-2, VEGF-2 gene trans

112 Inflammation was induced in C57BL/6 mice by subcutaneous injection of complete Freund adjuvant in th

113 ion, an inflammatory reaction was induced by subcutaneous injection of Complete Freund's Adjuvant in

114 ) mice were treated with a single 200-microg subcutaneous injection of CRP or control reagents either

115 omly assigned to receive either a once-daily subcutaneous injection of dalteparin (5,000 IU), a low m

116 xpression of IL-33 in quiescent vessels, and subcutaneous injection of DAPT in healthy skin reduced I

117 ent on CD11c+ dendritic cells (DCs), and the subcutaneous injection of DCs is sufficient to trigger e

118 and litters exposed to MS15 with concurrent subcutaneous injection of devazepide or vehicle.

119 eptive stimulation was carried out through a subcutaneous injection of dilute formalin (50muL, 10%) i

120 computer-generated blocked randomisation to subcutaneous injection of either 2 mg/kg (maximum 300 mg

121 Animals received a subcutaneous injection of either 250,000 cells of the tr

122 We randomly assigned patients to receive a subcutaneous injection of either erenumab, at a dose of

123 cificity in mouse models that had received a subcutaneous injection of either live (infection/inflamm

124 d participants (1:1) by country to receive a subcutaneous injection of either mepolizumab 100 mg or p

125 Two groups of 12 rats received a single subcutaneous injection of either normal saline or pegfil

126 were randomly assigned to receive one daily subcutaneous injection of enoxaparin 40 mg or placebo un

127 In a syngeneic model of tumor progression, subcutaneous injection of EO771 cells formed faster-grow

128 tudied on two occasions, with a double-blind subcutaneous injection of EX (5 mug) or placebo (PLC) 30

129 BALB/c mice received subcutaneous injection of FITC-conjugated dextran (DX) p

130 Healthy volunteers received a single subcutaneous injection of fitusiran (at a dose of 0.03 m

131 hology) infiltration were investigated after subcutaneous injection of free porcine aortic ECs (PAEs)

132 r results indicated that subconjunctival and subcutaneous injection of HC-HA/PTX3 preserved tear secr

133 ammatory and vascular changes in response to subcutaneous injection of heat-killed Escherichia coli.

134 The hypothesis was tested by means of subcutaneous injection of human muscle precursor cells f

135 mg per deciliter in a 3:1 ratio to receive a subcutaneous injection of inclisiran or placebo in eithe

136 veitis (EAU) was induced in B10.RIII mice by subcutaneous injection of interphotoreceptor retinoid-bi

137 ly assigned participants to receive a single subcutaneous injection of ISIS-APO(a)Rx (50 mg, 100 mg,

138 A recent study demonstrated that a single subcutaneous injection of isoproterenol (ISO; 200 mg/kg)

139 Subcutaneous injection of jacalin into neonatal mice dra

140 ulation, 53 women were administered a single subcutaneous injection of kisspeptin-54 (1.6 nmol/kg, n

141 EIU was induced by subcutaneous injection of lipopolysaccharide (LPS) (200

142 EIU in Lewis rats was induced by subcutaneous injection of lipopolysaccharide (LPS) follo

143 EIU in Lewis rats was developed by subcutaneous injection of lipopolysaccharide (LPS; 150 m

144 EIU in Lewis rats was developed by the subcutaneous injection of lipopolysaccharide (LPS; 150 m

145 EIU was induced by subcutaneous injection of lipopolysaccharide (LPS; 150 m

146 Treatment for 16 weeks with once-daily subcutaneous injection of liraglutide or placebo.

147 Acute renal failure was induced by 5 mg/kg subcutaneous injection of mercuric chloride in BALB/c mi

148 synaptosomes, and in striatum of rats given subcutaneous injection of METH.

149 Subcutaneous injection of mice with PF-04178903 was init

150 male mice were exposed to a single 50-microg subcutaneous injection of mouse Y1 or mouse Y3 RNA, and

151 duced in these animals (and controls) by the subcutaneous injection of myelin oligodendrocyte glycopr

152 Mice in pretreatment were treated with a subcutaneous injection of N-acetylcysteine before the fo

153 Blocking studies were performed by subcutaneous injection of nicotine (10 mg/kg).

154 Subcutaneous injection of NOD SCID mice with IPAH CFU-EC

155 d during antigen-induced inflammation due to subcutaneous injection of ovalbumin at the heel or at th

156 Subcutaneous injection of PEG-PH20 delays the onset of E

157 Using both subcutaneous injection of QD-tagged cancer cells and sys

158 Furthermore, subcutaneous injection of recombinant TWEAK into naive m

159 n experimental group which received a weekly subcutaneous injection of RhEPO (150 IU kg(-1); n = 8),

160 e performed on tumor-bearing nude mice after subcutaneous injection of RIN-m5F cells.

161 Subcutaneous injection of SIB-1508Y (10 mg/kg) increased

162 In this model, subcutaneous injection of SK5 cells with short hairpin R

163 control group (CON) which received a weekly subcutaneous injection of sterile saline (10 ml; n = 7)

164 Participants received a subcutaneous injection of TDV or placebo on days 0 and 9

165 Our studies showed that the subcutaneous injection of the Ad-sig-TAA/ecdCD40L vector

166 segment (ROS) interface were observed after subcutaneous injection of the drug-loaded delivery combi

167 ections with saline (control); (ii) a single subcutaneous injection of the gonadotropin-releasing hor

168 tion of the jugular vein was performed after subcutaneous injection of the peptide in rats (n=4 per p

169 Subcutaneous injection of the PGE(2) analog misoprostol

170 A single subcutaneous injection of the same variant in rabbits re

171 After a single subcutaneous injection of the vascular endothelial growt

172 onic hypoxia ( approximately 10% O(2)) after subcutaneous injection of the vascular endothelial growt

173 In wild-type mice, the subcutaneous injection of trehalose dimycolate-coated po

174 Subcutaneous injection of TRIM24 iHMECs in nude mice led

175 When monitored after skin organ culture or subcutaneous injection of tumor necrosis factor alpha, L

176 This was immediately followed by subcutaneous injection of vehicle, mifepristone 30 mg/kg

177 Subcutaneous injection of XPC-deficient keratinocytes in

178 range, 30-85 years) who received intradermal subcutaneous injections of 0.31-100 microg indocyanine g

179 re randomly assigned to receive seven weekly subcutaneous injections of 1 mg or 3 mg of anti-interleu

180 One hundred patients received subcutaneous injections of 1 mg twice per day of CrA and

181 ted (1:1) by an external service provider to subcutaneous injections of 10(8) plaque-forming units of

182 derate-to-severe plaque psoriasis to receive subcutaneous injections of 10, 25, 75, or 150 mg of ixek

183 atients were enrolled to receive once weekly subcutaneous injections of 180 microg peginterferon alfa

184 parate experiment, Ldlr(-/-) mice were given subcutaneous injections of 27HC and placed on regular ch

185 Subcutaneous injections of 500 mug of lipid-free apoA-I

186 Repeated subcutaneous injections of a monoclonal antibody against

187 , or their littermates (controls) were given subcutaneous injections of a syngeneic KPC-derived PDAC

188 ent peripheral corneal infiltrates following subcutaneous injections of adalimumab.

189 Activation of Tie2 by subcutaneous injections of AKB-9778 combined with suppre

190 scid)Il2rg(tm1Wjl)/SzJ (NSG) mice were given subcutaneous injections of AMC-EAC-007B cells and also g

191 Mice were treated with single subcutaneous injections of AMD3100 (5 mg/kg) or saline a

192 40 mg, or matching placebo every 2 weeks; or subcutaneous injections of AMG 145 280 mg, 350 mg, or 42

193 ough an interactive voice response system to subcutaneous injections of AMG 145 70 mg, 105 mg, or 140

194 ugh an interactive voice response system, to subcutaneous injections of AMG 145 70 mg, 105 mg, or 140

195 were randomly assigned to receive six weekly subcutaneous injections of AMG 531 (1, 3, or 6 microg pe

196 Its pharmacological inhibition by subcutaneous injections of an anti-myostatin peptibody i

197 After repeated subcutaneous injections of anti-mLAMalpha3 IgG erosions

198 We also determined the effect of subcutaneous injections of AZD8529 (20 and 40 mg/kg) on

199 for cancer treatment received two successive subcutaneous injections of azoxymethane (AOM) at 20mg/kg

200 ce using a model of skin fibrosis induced by subcutaneous injections of bleomycin.

201 er avoidance stress each day, or given daily subcutaneous injections of corticosterone, for 10 consec

202 Weekly subcutaneous injections of drug nanoformulations at dose

203 Three subcutaneous injections of each conjugate formulated wit

204 of intra-abdominal sepsis, followed by daily subcutaneous injections of either 1 mL of iron dextran (

205 with moderate-to-severe psoriasis to receive subcutaneous injections of either 45 or 90 mg of ustekin

206 randomized to groups that were given up to 6 subcutaneous injections of either etanercept or placebo

207 BN rats received subcutaneous injections of either saline or one of two d

208 C57BL/6 mice were untreated (UT) or received subcutaneous injections of either scopolamine hydrobromi

209 Four days later, animals received daily subcutaneous injections of either the synthetic GLP-1 re

210 were randomized to 3 months monotherapy with subcutaneous injections of elamipretide (0.5 mg/kg once

211 Daily subcutaneous injections of enoxacin, bis-enoxacin, alend

212 lly, subsequent studies tested the mice with subcutaneous injections of etidronate.

213 ease were randomly assigned (1:1) to receive subcutaneous injections of exenatide 2 mg or placebo onc

214 previous cardiovascular disease, to receive subcutaneous injections of extended-release exenatide at

215 were randomized (1:1) to received 4 weeks of subcutaneous injections of GM-CSF (leukine), 500 mug/day

216 Subcutaneous injections of golimumab or placebo were adm

217 It involves subcutaneous injections of granulocyte-colony-stimulatin

218 Subcutaneous injections of ibuprofen via minipumps to ra

219 On days 2, 4, and 6, subjects received subcutaneous injections of IFN-gamma (100 mug/day; n = 6

220 ed study, and 488 of these patients received subcutaneous injections of IFN-gamma1b 100 microg (group

221 n overload was induced with one to 15 weekly subcutaneous injections of iron dextran.

222 gle-dose part of the study or to receive six subcutaneous injections of ISIS-APO(a)Rx (100 mg, 200 mg

223 y weight, while receiving either twice daily subcutaneous injections of leptin or placebo.

224 nducted in four UK medical centres to assess subcutaneous injections of liraglutide (1.8 mg daily) co

225 atients in a 2:1 ratio to receive once-daily subcutaneous injections of liraglutide at a dose of 3.0

226 The mBT regimen consisted of outpatient subcutaneous injections of low-dose IL-2 (1 MIU/m(2)) 5/

227 -2Rgamma(-/-) (NSG) mice were given cecal or subcutaneous injections of LS-174T or human primary CRC

228 ce wheel-running behavior in response to 3 d subcutaneous injections of melatonin in the late day.

229 Single subcutaneous injections of mice with either mouse Y1 RNA

230 ere randomly assigned to receive five weekly subcutaneous injections of miravirsen at doses of 3 mg,

231 ntly 5 or 12 weeks later boosted by 3 weekly subcutaneous injections of MVATG16643.

232 EAE mice were given subcutaneous injections of myelin oligodendrocyte glycop

233 reactivity was immunized by a skin graft and subcutaneous injections of peripheral blood monocyte cel

234 psoriasis were randomly assigned to receive subcutaneous injections of placebo (n = 113), golimumab

235 ed to a double-blind trial of 12 once-weekly subcutaneous injections of placebo or 0.8 mg of etanerce

236 omputer-generated random sequence to receive subcutaneous injections of placebo or 315 mg LY at weeks

237 ose group) were randomly assigned to receive subcutaneous injections of placebo or an antisense oligo

238 studies to an in vivo setting, we performed subcutaneous injections of PPARgamma-expressing fibrobla

239 rats, ovariectomized for 1 week, were given subcutaneous injections of PPT (10 mg kg(-)(1)), oestrad

240 g or object recognition tasks; rats received subcutaneous injections of progesterone (500 microg) or

241 en-label, phase 1, multicentre trial, single subcutaneous injections of rAvPAL-PEG were given in esca

242 d glucose levels many times a day along with subcutaneous injections of recombinant DNA-derived insul

243 randomized double-blind comparison of weekly subcutaneous injections of rilonacept (160 mg) versus pl

244 assigned a total of 166 patients to receive subcutaneous injections of risankizumab (a single 18-mg

245 the standard of care (77 patients) or weekly subcutaneous injections of romiplostim (157 patients).

246 Children received subcutaneous injections of romiplostim (n = 17) or place

247 0(9)/L or less were randomly assigned 2:1 to subcutaneous injections of romiplostim (n=42 in splenect

248 Animals received subcutaneous injections of saline or liraglutide (0.005-

249 were randomly assigned to group 1 (control): subcutaneous injections of saline solution, three times

250 Following ethanol exposure, pups received subcutaneous injections of saline vehicle or choline chl

251 sitized to EC with repeated (days 0, 21, 35) subcutaneous injections of saline-suspended porcine EC (

252 Participants self-administered daily subcutaneous injections of tesamorelin (Theratechnologie

253 chemotherapy alone [n = 1]) received up to 6 subcutaneous injections of the IL-2/CD40L vaccine.

254 Multiple subcutaneous injections of the insulin containing formul

255 erol, 15% lard) without or with twice weekly subcutaneous injections of the proteasome inhibitor (PSI

256 Subcutaneous injections of the selective 5-HT(1A) agonis

257 Subcutaneous injections of these complexes showed enhanc

258 underwent a second randomization to receive subcutaneous injections of ustekinumab (90 mg) or placeb

259 r wild-type donors, and treated with 7 daily subcutaneous injections of VIPhyb (peptidic VIP-antagoni

260 g/m(2)) was given as an intravenous bolus or subcutaneous injection on days 1, 4, 8, and 11 of 21-day

261 when administered at 10 or 100 microg/kg by subcutaneous injection once daily.

262 25 mg pitrakinra (n=12) or placebo (n=12) by subcutaneous injection once daily.

263 Y2951742 (150 mg) or placebo were given as a subcutaneous injection once every 2 weeks for 12 weeks.

264 Treatment consisted of subcutaneous injections once per week from week 1 to 4,

265 e chemiluminescence in vivo images following subcutaneous injection, only the NIR probe could provide

266 en receiving recombinant human PTH either by subcutaneous injection or by intravenous infusion.

267 of 0.1 microg/kg when administered by either subcutaneous injection or oral delivery.

268 increased their ability to form tumors after subcutaneous injection or orthotopic transplantation int

269 abel trial evaluated the effects of 4 weekly subcutaneous injections or 1 intravenous infusion of ust

270 ound that increasing ghrelin levels, through subcutaneous injections or calorie restriction, produced

271 peginterferon alfa 2a (180 mug once weekly, subcutaneous injection) or 2b (according to bodyweight;

272 tant therapy) to once-weekly exenatide (2 mg subcutaneous injection) or once-daily glargine (titrated

273 Treatments were administered by subcutaneous injection; patients assigned to 50 mg siruk

274 em, to receive once-weekly exenatide 2 mg by subcutaneous injection plus once-daily dapagliflozin 10

275 g, 100 mug, 120 mug, or 150 mug once weekly, subcutaneous injection), plus ribavirin (1000-1200 mg/da

276 administration of 20-40 mug/kg/d of IL-15 by subcutaneous injection resulted in a more modest (10-fol

277 1 inhibitor preparation that is suitable for subcutaneous injection, resulted in functional levels of

278 bution and PET studies after intravenous and subcutaneous injections showed similar patterns and kine

279 Simvastatin treatment (20mg/kg, bolus subcutaneous injection) significantly improved clinical

280 local skin inflammatory reaction limited to subcutaneous injection site and elicited no other toxic

281 of a novel in vitro system, termed Scissor (Subcutaneous Injection Site Simulator).

282 domly assigned 323 patients to receive three subcutaneous injections, spaced 4 weeks apart, of omaliz

283 e (n = 154) or placebo (n = 146) via a daily subcutaneous injection; study drug was advanced to a dos

284 omiplostim is a TPO peptide mimetic given by subcutaneous injection that activates the TPO receptor b

285 uble macromolecular complexes at the site of subcutaneous injection, thereby securing slow absorption

286 y 2 weeks off) or IFN-alpha (9 million units subcutaneous injections, three times weekly).

287 On subcutaneous injection to neonatal mice, the TLR8 agonis

288 to self-administer a single 30-mg icatibant subcutaneous injection to treat their next attack.

289 d aluminum hydroxide) were administered as 5 subcutaneous injections to 239 adults with allergic rhin

290 ined to open-label nadroparin (3800 IU daily subcutaneous injections) treatment (n = 67) in the setti

291 Pegfilgrastim 6 mg subcutaneous injection was administered 1 day after the

292 tial loading dose of 300 mg of rilonacept by subcutaneous injection, were evaluated 6 and 10 days lat

293 We have found that daily subcutaneous injection with a maximum tolerated dose (MT

294 Lastly, we showed in mice that subcutaneous injection with recombinant IL-17A, IL-22, o

295 nergy expenditure in mice was measured after subcutaneous injection with vehicle, 1 mg norepinephrine

296 thin 14 days of hospital discharge, to daily subcutaneous injections with anakinra 100 mg for 2 weeks

297 ed by geographical region, to receive weekly subcutaneous injections with atacicept (25, 75, or 150 m

298 nificantly different (p>0.05) as compared to subcutaneous injection, with a relative bioavailability

299 : oral gavage, intraperitoneal injection, or subcutaneous injection, with doses varying between 2 and

300 All patients received weekly subcutaneous injections, with the active treatment group